Entasis Therapeutics Holdings Inc. announced the appointment of Howard Mayer, M.D to its board of directors, effective immediately. Dr. Mayer has over 25 years of medical, clinical and executive experience in the life sciences industry. Dr. Mayer was Senior Vice President, Chief Medical Officer and Global Head of R&D, Neuroscience Division at Shire Pharmaceuticals. While at Shire, he also served as Senior Vice President and Head of Clinical Development. On August 5, 2019, the Board of Directors of the company appointed Howard Mayer, M.D. to serve as a Class II member of the Board, to serve until the 2020 annual meeting of stockholders or until his successor is duly elected and qualified. Concurrent with his appointment as a director, Dr. Mayer was appointed to the Compensation Committee of the Board. Dr. Mayer fills an existing vacancy on the Board.